Enveric Biosciences Net Worth
Enveric Biosciences Net Worth Breakdown | ENVB |
Enveric Biosciences Net Worth Analysis
Enveric Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Enveric Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Enveric Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Enveric Biosciences' net worth analysis. One common approach is to calculate Enveric Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Enveric Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Enveric Biosciences' net worth. This approach calculates the present value of Enveric Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Enveric Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Enveric Biosciences' net worth. This involves comparing Enveric Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Enveric Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Enveric Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enveric Biosciences' net worth research are outlined below:
| Enveric Biosciences generated a negative expected return over the last 90 days | |
| Enveric Biosciences has high historical volatility and very poor performance | |
| Enveric Biosciences has some characteristics of a very speculative penny stock | |
| Enveric Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (17.29 M) with profit before overhead, payroll, taxes, and interest of 8.15 M. | |
| Enveric Biosciences currently holds about 18.01 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enveric Biosciences has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2025 |
Enveric Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enveric Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enveric Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Enveric Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enveric Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enveric Biosciences backward and forwards among themselves. Enveric Biosciences' institutional investor refers to the entity that pools money to purchase Enveric Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Group One Trading, Lp | 2024-09-30 | 273 | Bank Of America Corp | 2024-09-30 | 173 | Nelson, Van Denburg & Campbell Wealth Management Group, Llc | 2024-09-30 | 50.0 | Wells Fargo & Co | 2024-09-30 | 16.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Fmr Inc | 2024-09-30 | 0.0 | Org Partners Llc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Mather Group, Inc. | 2024-09-30 | 0.0 | Advisorshares Investments, Llc | 2024-09-30 | 367 K | Geode Capital Management, Llc | 2024-09-30 | 217.9 K |
Follow Enveric Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.6 M.Market Cap |
|
Project Enveric Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.00 | (0.01) | |
| Return On Capital Employed | (9.67) | (9.19) | |
| Return On Equity | (0.01) | (0.01) |
When accessing Enveric Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Enveric Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enveric Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Enveric Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enveric Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enveric Biosciences' management manipulating its earnings.
Evaluate Enveric Biosciences' management efficiency
Enveric Biosciences has return on total asset (ROA) of (0.805) % which means that it has lost $0.805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.061) %, meaning that it created substantial loss on money invested by shareholders. Enveric Biosciences' management efficiency ratios could be used to measure how well Enveric Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 18, 2025, Return On Tangible Assets is expected to decline to -0.0051. The current year's Return On Capital Employed is expected to grow to -9.19. At present, Enveric Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 714 K, whereas Non Current Assets Total are forecasted to decline to about 784.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.04 | 0.99 | |
| Tangible Book Value Per Share | 0.93 | 0.98 | |
| Enterprise Value Over EBITDA | (0.03) | (0.03) | |
| Price Book Value Ratio | 1.65 | 1.57 | |
| Enterprise Value Multiple | (0.03) | (0.03) | |
| Price Fair Value | 1.65 | 1.57 | |
| Enterprise Value | 596.6 K | 566.8 K |
The leadership approach at Enveric Biosciences' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 1.7579 | Revenue | Quarterly Revenue Growth (0.07) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enveric Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enveric Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enveric Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enveric Biosciences time-series forecasting models is one of many Enveric Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Enveric Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Enveric Biosciences Earnings per Share Projection vs Actual
Enveric Biosciences Corporate Management
| Joseph Tucker | CEO Director | Profile | |
| Ibrahim MD | Chief Officer | Profile | |
| MBA IV | Interim Officer | Profile | |
| Peter Facchini | Chief Officer | Profile | |
| Avani Kanubaddi | Pres COO | Profile | |
| Kevin CPA | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.45) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.